PRIDE-HD, sponsored by Teva Pharmaceuticals
Pride-HD is a Phase II clinical research study of an investigational drug called pridopidine in peoplewho have a diagnosis of Huntington disease (HD). The purpose of this randomized, double blind study is to see what effect the investigational drug, pridopidine, has on movement, thinking, and behaviour, compared to placebo, in people with Huntington disease after 26 weeks of receiving either pridopidine or placebo. In addition, information will be collected about safety and tolerability of pridopidine in people with HD. This study has now fully recruited all patients needed for the trial.